Videos

Iwach Delivers State of Glaucoma Therapy. What’s Next?

By Mario Admin | December 16, 2017

Few can track the past 10 years of advances in glaucoma treatment as well as Andrew Iwach, MD, executive director of the Glaucoma Center of…

Read More

Alimera Sees Bright Spots in 2018

By Mario Admin | December 16, 2017

Dan Myers, CEO of Alimera Sciences, says company growth is moving the firm into cash-positive territory in 2018. What challenges did he have to conquer…

Read More

CEO Roesky Sees Dry Eye Challenges as Opportunities for Novaliq

By Mario Admin | December 16, 2017

Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing…

Read More

Boorady Explains How TearScience Can Help “Bridge the O’s”

By Mario Admin | December 16, 2017

Joe Boorady, OD, president & CEO of TearScience, details the rollout of the company’s dry eye suite of tools now that it’s part of Johnson…

Read More

Gadek Compares, Contrasts SARcode and TearSolutions

By Mario Admin | December 16, 2017

Tom Gadek, president and CEO of dry eye start-up TearSolutions, explains how his “religious vision quest” at SARcode Bioscience, the entity that developed the drug…

Read More
Iconic

Iconic Eyes Phase IIb for Lead Candidate in 2018

By Mario Admin | December 15, 2017

Iconic Therapeutics is looking to take a significant step in ophthalmology in 2018, William Greene, MD, CEO, said during the Company Showcase 3 session at…

Read More
Private Funding Trends Presentation

SVB’s Norris Sees Surge in Strategics, Venture Dollars

By Mario Admin | December 12, 2017

Jonathan Norris, managing director at Silicon Valley Bank, points to increased fund-raising by healthcare-focused venture capital firms and a surge by strategic investors in Series…

Read More
A View of the Public Ophthalmology Market

Piper Jaffray’s Gitkin Delivers Good News about Ophthalmology Stocks

By Mario Admin | December 12, 2017

Piper Jaffray managing director Andrew Gitkin, head of West Coast biotech investment banking, delivers good news to attendees of OIS@AAO. Overall public markets are strong,…

Read More

Mazzo: Innovation in Ophthalmology Remains Strong

By Mario Admin | December 10, 2017

Industry stalwart Jim Mazzo, global president, ophthalmology atd Zeiss, delivers his assessment of the state of innovation in ophthalmology.

Read More

Dempsey: Shire Going Global with Xiidra

By Mario Admin | December 10, 2017

Robert Dempsey, group vice president and head, global ophthalmics franchise, lays out Shire’s plans to roll out Xiidra worldwide. What are the challenges? Where will…

Read More

Global Head Ehrlich Reviews Genentech’s Strong Position in Ophthalmology

By Mario Admin | December 10, 2017

Jason Ehrlich, MD, PhD, the global head, clinical, of Genentech’s ophthalmology product development group, details the company’s current and future ophthalmology pipeline. He also looks…

Read More

Novartis’ Sauer Updates on AMD Trial, Sees Bright Future for Ophthalmology Innovation

By Mario Admin | December 10, 2017

Dirk Sauer, PhD, global development unit head of ophthalmology, lays out the next steps for Novartis’ potential AMD blockbuster. He also shares his views on…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.